Gaucher pill looks promising in Phase II; Discovery Labs shakes up executive team;

 @FierceBiotech: U.S. biotech faces fierce international competition. Article | Follow @FierceBiotech

> Genzyme is reporting that a mid-stage trial of a new pill for Gaucher disease was a success. Investigators are now recruiting patients for a Phase III study. Story

> Discovery Laboratories has shaken up its executive staff with a series of new assignments. And the developer says it plans to select a permanent CEO in 2011. Report

> AVI BioPharma reports that an animal study for its experimental H1N1 drug produced promising results. Article

> Harvard Bioscience, which makes tools for drug researchers, is buying Coulbourn Instruments. Item

> Kamada will get a $20 million upfront payment from Baxter after inking a distribution deal for the newly approved Glassia, a new emphysema therapy. Report

> Soligenix has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Products Development. Soligenix release

> Celsion says that the FDA has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation as a fast track development program. Celsion release

And Finally... Scientists have mapped the points at which vitamin D interacts with our DNA--and identified over two hundred genes that it directly influences. Release